Presenter: Medeya Tsnobiladze, ND, MS

Original Date: August 14, 2022

Alzheimer’s (AD) and Parkinson’s (PD) diseases are the two most prevalent neurodegenerative conditions in the USA. They together affect over 7 million people. While very different clinically, these two conditions have similar pathophysiologic features. While initially affecting different groups of neurons, both conditions lead to neuronal loss. Proteinaceous aggregations found in Alzheimer’s and Parkinson’s are different, but both conditions are kinds of amyloidosis. There is a growing body of data showing that both these neurodegenerative conditions can be connected to gut health and microbiome disruption that may precede the onset of AD and PD by years, if not decades.

In this presentation we will explore mechanisms by which processes in the gut may start neurodegeneration in the brain, characteristic microbiome changes, and possible interventions that may prevent or slow down progression of the disease.

1.25 General and 0.25 Pharmacology (Total 1.5 CEUs) approved by OBNM